Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy
Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved..
One of the ways in which macrophages support tumorigenic growth is by producing adenosine, which acts to dampen antitumor immune responses and is generated by both tumor and immune cells in the tumor microenvironment (TME). Two cell surface expressed molecules, CD73 and CD39, boost catalytic adenosine triphosphate, leading to further increased adenosine synthesis, under hypoxic circumstances in the TME. There are four receptors (A1, A2A, A2B, and A3) expressed on macrophages that allow adenosine to perform its immunomodulatory effect. Researchers have shown that adenosine signaling is a key factor in tumor progression and an attractive therapeutic target for treating cancer. Several antagonistic adenosine-targeting biological therapies that decrease the suppressive action of tumor-associated macrophages have been produced and explored to transform this result from basic research into a therapeutic advantage. Here, we'll review the newest findings from studies of pharmacological compounds that target adenosine receptors, and their potential therapeutic value based on blocking the suppressive action of macrophages in tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Human immunology - (2024) vom: 22. März, Seite 110774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Han [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adenosine |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.humimm.2024.110774 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370112261 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370112261 | ||
| 003 | DE-627 | ||
| 005 | 20240324235525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.humimm.2024.110774 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370112261 | ||
| 035 | |a (NLM)38521664 | ||
| 035 | |a (PII)S0198-8859(24)00030-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Han |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a One of the ways in which macrophages support tumorigenic growth is by producing adenosine, which acts to dampen antitumor immune responses and is generated by both tumor and immune cells in the tumor microenvironment (TME). Two cell surface expressed molecules, CD73 and CD39, boost catalytic adenosine triphosphate, leading to further increased adenosine synthesis, under hypoxic circumstances in the TME. There are four receptors (A1, A2A, A2B, and A3) expressed on macrophages that allow adenosine to perform its immunomodulatory effect. Researchers have shown that adenosine signaling is a key factor in tumor progression and an attractive therapeutic target for treating cancer. Several antagonistic adenosine-targeting biological therapies that decrease the suppressive action of tumor-associated macrophages have been produced and explored to transform this result from basic research into a therapeutic advantage. Here, we'll review the newest findings from studies of pharmacological compounds that target adenosine receptors, and their potential therapeutic value based on blocking the suppressive action of macrophages in tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a Adenosine Receptors | |
| 650 | 4 | |a Pharmacological Agents | |
| 650 | 4 | |a Tumor Associated Macrophages | |
| 700 | 1 | |a Zhang, Zongliang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yulian |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Xinbao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Guanqun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhenlin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xuechuan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xueyu |e verfasserin |4 aut | |
| 700 | 1 | |a He, Tianzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human immunology |d 1993 |g (2024) vom: 22. März, Seite 110774 |w (DE-627)NLM012629065 |x 1879-1166 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |g pages:110774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.humimm.2024.110774 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 03 |h 110774 | ||